Status:

RECRUITING

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

Lead Sponsor:

University of Virginia

Conditions:

Cystic Fibrosis (CF)

Chronic Kidney Disease(CKD)

Eligibility:

All Genders

7+ years

Brief Summary

The purpose of this study is to find out what causes kidney disease in people with CF. The investigators will study biomarkers in the blood and urine that can either predict who is at risk or detect k...

Detailed Description

The prevalence of chronic kidney disease is significantly increased in patients with cystic fibrosis (PwCF) with a major impact on morbidity and medication tolerance as people age. Although expressed ...

Eligibility Criteria

Inclusion

  • Outpatient CF Cohort
  • Diagnoses of Cystic Fibrosis
  • Age \> 30 years old
  • Able to provide informed consent
  • Inpatient CF Cohort
  • Diagnoses of Cystic Fibrosis
  • Age \> 7 years old
  • Able to provide informed consent and assent (where applicable)
  • 55 PwCF frequently hospitalized for a pulmonary exacerbation (\>1 hospital admission in the prior 12 months)
  • 55 PwCF sporadically hospitalized for a pulmonary exacerbation (no hospital admissions in the prior 12 months)
  • Able to provide urine sample independently
  • Healthy Controls
  • Healthy, as per participant self-report
  • Age between 30-50 years
  • Able to provide informed consent

Exclusion

  • Outpatient CF Cohort
  • History of any organ transplant
  • History of immunodeficiency
  • Previous or current cancer diagnoses
  • Pregnant or breastfeeding
  • On chronic dialysis
  • Non-compliance (demonstrated by \<2 visits during the 12 months before enrollment)
  • Inpatient CF Cohort
  • The initiation of intravenous antibiotic therapy after hospital admission before obtaining the first blood and urine sample
  • History of any organ transplant
  • History of immunodeficiency
  • Previous or current cancer diagnoses
  • Pregnant or breastfeeding
  • On chronic dialysis
  • Healthy Controls
  • History or current kidney disease, organ transplantation, cancer, or any other chronic illness
  • Current use of antibiotics
  • Urinary symptoms or UTI (dysuria, frequency, urgency)
  • Pregnant women
  • Menstruating on the study visit day
  • Blood relatives of PwCF

Key Trial Info

Start Date :

January 9 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

260 Patients enrolled

Trial Details

Trial ID

NCT06595420

Start Date

January 9 2025

End Date

December 1 2027

Last Update

April 15 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233

2

Dartmouth-Hitchcock Geisel School of Medicine at Dartmouth

Lebanon, New Hampshire, United States, 03756

3

University of Virginia Children's Hospital

Charlottesville, Virginia, United States, 22908